07:00 , Aug 1, 2016 |  BioCentury  |  Strategy

Bug battle plan

Tired of waiting for the international community to organize proactive responses to the threats posed by emerging infectious diseases, GlaxoSmithKline plc has developed plans and is soliciting government support to create a permanent, independent entity...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Company News

Five Prime, GlaxoSmithKline deal

GlaxoSmithKline gave a 180-day notice to terminate a 2011 deal with Five Prime granting the pharma exclusive rights in the U.S., EU and Canada to develop and commercialize cancer candidate FP-1039 . The original deal...
03:21 , Mar 11, 2016 |  BC Extra  |  Company News

GSK ending deal for Five Prime's FP-1039

Five Prime Therapeutics Inc. (NASDAQ:FPRX) said GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) gave it 180-day notice that it is terminating a 2011 deal and returning rights to FP-1039 , which is in a Phase Ib trial for...
08:00 , Nov 16, 2015 |  BioCentury  |  Product Development

On SLE's trail

AstraZeneca plc's MedImmune LLC unit is following a clinical development trail for lupus candidate anifrolumab first blazed by Benlysta belimumab. The company hopes that its track record of successful mid-stage trials in the indication have...
07:00 , Aug 10, 2015 |  BioCentury  |  Finance

And then there were two

After 20 years and about $1.3 billion raised, Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) has had its first Phase III success with telotristat etiprate to treat carcinoid syndrome. The company hopes to double its Phase III hit...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Company News

Inotek management update

Inotek Pharmaceuticals Corp. , Lexington, Mass.   Business: Ophthalmic, Renal, Autoimmune   Hired: David Southwell as president, CEO and a director, formerly EVP and CFO of Human Genome Sciences Inc. , which GlaxoSmithKline plc acquired...
07:00 , May 19, 2014 |  BC Week In Review  |  Clinical News

Darapladib: Phase III data

Top-line data from the double-blind, international Phase III SOLID-TIMI 52 trial in >13,000 patients who began treatment within 30 days following an ACS showed that once-daily 160 mg oral darapladib plus standard of care (SOC)...
01:30 , May 14, 2014 |  BC Extra  |  Clinical News

GSK's darapladib misses in Phase III ACS trial

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said once-daily oral darapladib ( SB-480848 ) plus standard of care (SOC) missed the primary endpoint vs. placebo plus SOC in the Phase III SOLID-TIMI 52 trial to treat acute coronary...
07:00 , Apr 28, 2014 |  BioCentury  |  Strategy

GSK's special feeling

Nearly 15 years after Glaxo Wellcome plc and SmithKline Beecham plc merged to form the world's largest drug company, GlaxoSmithKline plc is steadily downsizing to focus on areas like vaccines and respiratory diseases where it...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Clinical News

Darapladib: Additional Phase III data

Additional data from the double-blind, international Phase III STABILITY trial in 15,828 patients with chronic CHD showed that once-daily 160 mg oral darapladib plus standard of care (SOC) met the secondary endpoints of reducing the...